Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients with Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

429

Participants

Timeline

Start Date

May 10, 2017

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced Gastric or EGJ Cancer
Interventions
DRUG

FOLFIRI

Irinotecan 180 mg/m2; i.v. bolus of 5-FU 400 mg/m2, i.v. infusion of leucovorin\* 400 mg/m2 , followed by a 46-hour continuous administration of 5-FU 2400 mg/m2 on day 1 and 15 of a 28-day cycle

DRUG

Ramucirumab

8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle

DRUG

Paclitaxel

80 mg/m2 on day 1, 8, 15

Trial Locations (16)

2700

Wiener Neustadt, Landesklinikum, Wiener Neustadt

4010

Ordensklinikum Linz GmbH, Barmherzige Schwestern, Linz

6830

Landeskrankenhaus Feldkirch - Rankweil, Rankweil

81675

Technische Universität München, München

Unknown

HELIOS Klinikum Bad Saarow, Bad Saarow

Charité - Universitätsmedizin Berlin, Berlin

HELIOS Klinikum Berlin Buch, Berlin

Klinikum Bielefeld Mitte, Bielefeld

Kliniken Essen Mitte, Essen

Krankenhaus Nordwest, Frankfurt

Hämatologisch-Onkologische Praxis Eppendorf (HOPE), Hamburg

Ortenau Klinikum, Lahr

Universitäres Krebszentrum Leipzig, Leipzig

Universitätsklinikum Tübingen, Tübingen

Universitätsklinikum Ulm, Ulm

U.O. Oncologia Medica, Università Cattolica Sacro Cuore, Rome

All Listed Sponsors
lead

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

OTHER